About admin

This author has not yet filled in any details.
So far admin has created 39 blog entries.

20 Years Later: A Cancer DNA Load Blood Test

Chronix Biomedical

Chronix Biomedical filed its first patent application 20 years ago on October 4, 1996. This first patent application has subsequently led to a series of exciting developments culminating in revolutionary genetic testing technology to diagnose...

By | October 4th, 2016|Chronix news|0 Comments

#TheTurningPointInCancerFight

Chronix Biomedical

Exactly 20 years ago, on 4th of October 1996, Howard Urnovitz, founder and CEO of Chronix Biomedical, an innovative biomedical company from Palo Alto (California, US), has applied for a Patent, which was the result...

By | October 4th, 2016|Chronix news|0 Comments

Chronix Biomedical welcomes moves to define new regulatory standards in liquid biopsy field

Chronix Biomedical

San Jose, CA, USA and Göttingen, Germany (20 July 2016) – Chronix Biomedical, Inc., a developer of blood-based molecular diagnostics, welcomes the recent moves to more clearly define US regulatory standards for the use of...

By | July 20th, 2016|Chronix news|0 Comments

Cell Free DNA accurately correlates with breast cancer DNA

Howard B. Urnovitz, Modulation of breast cancer cell-free DNA with surgical resection. J Clin Oncol 31, 2013 (suppl; abstr 11060)

Researchers from Chronix Biomedical and The University of Texas MD Anderson Cancer Center announced results from a pilot study demonstrating the utility of cell-free DNA (cfDNA) blood tests as a companion diagnostic for breast cancer patients at the American Society of Clinical Oncology Annual Meeting (ASCO 2013).

By | July 3rd, 2016|Other publications|0 Comments

Chronix Biomedical’s serum DNA assays can monitor disease activity and treatment response in multiple sclerosis

Chronix Biomedical

San Jose, California, April 6, 2010 – Chronix Biomedical today announced publication of a study that supports the utility of its serum DNA blood tests to predict clinical status and monitor disease activity and response to...

By | June 3rd, 2016|Chronix news|0 Comments

New study shows blood test detected cancer metastasis

Chronix Biomedical

RESEARCH BY CHRONIX BIOMEDICAL AND INSTITUTE OF VETERINARY MEDICINE GÖTTINGEN HIGHLIGHTS CELL-FREE DNA ANALYSIS FOR CANCER MINIMAL RESIDUAL DISEASE San Jose, CA and Göttingen, Germany—September 30, 2013—Researchers from the University Göttingen Institute of Veterinary Medicine...

By | June 1st, 2016|Chronix news|0 Comments

Detection of novel HPV mutations and chromosomal number imbalance

Newswise

Newswise — CHICAGO (May 30, 2014) – Researchers from Sanford Health and Chronix Biomedical today announced that results from a pilot study demonstrating the utility of a new cancer panel to detect previously undetected viral...

By | June 1st, 2016|Other publications|0 Comments

Chronix Biomedical to present clinical data on its cell-free DNA approach as an early predictor of response to immunotherapy at the ASCO Annual Meeting

Chronix Biomedical

San Jose, CA, USA and Göttingen, Germany (3 May, 2016) – Chronix Biomedical, Inc., a developer of blood-based molecular diagnostics, today announces that it will present clinical data relating to its cell-free DNA copy number...

By | May 3rd, 2016|Chronix news|0 Comments

Clinica Highlights Chronix Biomedical’s Diagnostics

Tina Tan, Chronix’s new liquid biopsy approach show promise as early predictor of cancer therapies. Clinica, 18 April 2016.

A blood-based test which looks at chromosomal gains and losses in cell-free DNA (cfDNA) has demonstrated its potential of being a predictor of how well cancer patients are responding to chemotherapy.

By | April 18th, 2016|Other publications|0 Comments